Manufacturing and Delivery Innovation

GenCART is advancing both ex vivo and in vivo CAR-T production platforms to broaden access and improve efficiency:

• Ex Vivo CAR-T Expansion System – Our traditional vein-to-vein manufacturing model enables autologous T cells to be collected, engineered, and expanded under controlled laboratory conditions before reinfusion. GenCART’s proprietary process is designed for greater scalability and cost reduction compared with existing commercial systems.
• In Vivo Expansion via Nanotechnology – In parallel, GenCART is developing a nanotechnology-based delivery system to induce CAR expression and expansion directly within the patient’s body. This approach could eliminate complex cell manufacturing altogether, making CAR-T therapy faster, more affordable, and accessible to a much larger patient population.